Revive Therapeutics (TSE:RVV) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Revive Therapeutics Ltd. has announced positive feedback from the FDA regarding the development of Bucillamine, a drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID. The FDA has advised the company to file a new IND application for Bucillamine, using data from their Phase 3 trial on mild to moderate COVID-19, to support their upcoming clinical trial for Long COVID. This comes as the company leverages previous research and aims to address the estimated 7.5% of U.S. adults suffering from Long COVID symptoms.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
